DigestRedComo funciona
Red
/
Empresas
Br
No verificado

Bristol Myers Squibb

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

125 Comunicados de prensa

Ver todos los comunicados de prensa
09/03/2026
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
07/03/2026
Industria
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Medicina - Varios
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
02/03/2026
Acciones y Obligaciones
Biotecnología
Farmacéutica
Salud
Bristol Myers Squibb Announces Dividend
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
26/02/2026
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
23/02/2026
Eventos
Web y redes sociales
Biotecnología
Sanidad
Farmacéutica
Salud
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
23/02/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Industria
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
17/02/2026
Oncología
Higiene alimentaria
Salud
Farmacéutica
Cardiología
Biotecnología
Industria
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
05/02/2026
Asociaciones/Profesionales
Salud
Finanzas
Sanidad
Farmacéutica
Biotecnología
Web y redes sociales
Telefonía
Mercado de valores
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
04/02/2026
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
03/02/2026
Mercado laboral
Industria
Biotecnología
Sanidad
Farmacéutica
Salud
Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0